Current perspectives of insulin resistance and polycystic ovary syndrome

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Aims To review the relationship between insulin resistance and polycystic ovary syndrome. Methods A literature review. Results Insulin resistance likely plays a central pathogenic role in polycystic ovary syndrome and may explain the pleiotropic presentation and involvement of multiple organ systems. Insulin resistance in the skeletal muscle of women with polycystic ovary syndrome involves both intrinsic and acquired defects in insulin signalling. The cellular insulin resistance in polycystic ovary syndrome has been further shown to involve a novel post-binding defect in insulin signal transduction. Treatment of insulin resistance through lifestyle therapy or with a diabetes drug has become mainstream therapy in women with polycystic ovary syndrome. However, effects with current pharmacologic treatment with metformin tend to be modest, with limited benefit as an agent to treat infertility. Insulin resistance contributes to increased risk for pregnancy complications, diabetes and cardiovascular disease risk profile in polycystic ovary syndrome, which is further exacerbated by obesity. While numerous studies demonstrate increased prevalence of cardiovascular disease risk factors in women with polycystic ovary syndrome, there are limited data showing that women with polycystic ovary syndrome are at increased risk for cardiovascular disease events. Conclusions Insulin resistance is linked to polycystic ovary syndrome. Further study of lifestyle and pharmacologic interventions that reduce insulin resistance, such as metformin, are needed to demonstrate that they are effective in reducing the risk of diabetes, endometrial abnormalities and cardiovascular disease events in women with polycystic ovary syndrome.

Original languageEnglish (US)
Pages (from-to)1445-1454
Number of pages10
JournalDiabetic Medicine
Volume28
Issue number12
DOIs
StatePublished - Dec 1 2011

Fingerprint

Polycystic Ovary Syndrome
Insulin Resistance
Cardiovascular Diseases
Metformin
Life Style
Uterine Diseases
Insulin
Pregnancy Complications
Therapeutics
Infertility
Signal Transduction
Skeletal Muscle
Obesity

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{dd8dc1baf0b84673aa2632437353d5e8,
title = "Current perspectives of insulin resistance and polycystic ovary syndrome",
abstract = "Aims To review the relationship between insulin resistance and polycystic ovary syndrome. Methods A literature review. Results Insulin resistance likely plays a central pathogenic role in polycystic ovary syndrome and may explain the pleiotropic presentation and involvement of multiple organ systems. Insulin resistance in the skeletal muscle of women with polycystic ovary syndrome involves both intrinsic and acquired defects in insulin signalling. The cellular insulin resistance in polycystic ovary syndrome has been further shown to involve a novel post-binding defect in insulin signal transduction. Treatment of insulin resistance through lifestyle therapy or with a diabetes drug has become mainstream therapy in women with polycystic ovary syndrome. However, effects with current pharmacologic treatment with metformin tend to be modest, with limited benefit as an agent to treat infertility. Insulin resistance contributes to increased risk for pregnancy complications, diabetes and cardiovascular disease risk profile in polycystic ovary syndrome, which is further exacerbated by obesity. While numerous studies demonstrate increased prevalence of cardiovascular disease risk factors in women with polycystic ovary syndrome, there are limited data showing that women with polycystic ovary syndrome are at increased risk for cardiovascular disease events. Conclusions Insulin resistance is linked to polycystic ovary syndrome. Further study of lifestyle and pharmacologic interventions that reduce insulin resistance, such as metformin, are needed to demonstrate that they are effective in reducing the risk of diabetes, endometrial abnormalities and cardiovascular disease events in women with polycystic ovary syndrome.",
author = "Jaimey Pauli and Nazia Raja-Khan and X. Wu and Richard Legro",
year = "2011",
month = "12",
day = "1",
doi = "10.1111/j.1464-5491.2011.03460.x",
language = "English (US)",
volume = "28",
pages = "1445--1454",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "12",

}

Current perspectives of insulin resistance and polycystic ovary syndrome. / Pauli, Jaimey; Raja-Khan, Nazia; Wu, X.; Legro, Richard.

In: Diabetic Medicine, Vol. 28, No. 12, 01.12.2011, p. 1445-1454.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current perspectives of insulin resistance and polycystic ovary syndrome

AU - Pauli, Jaimey

AU - Raja-Khan, Nazia

AU - Wu, X.

AU - Legro, Richard

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Aims To review the relationship between insulin resistance and polycystic ovary syndrome. Methods A literature review. Results Insulin resistance likely plays a central pathogenic role in polycystic ovary syndrome and may explain the pleiotropic presentation and involvement of multiple organ systems. Insulin resistance in the skeletal muscle of women with polycystic ovary syndrome involves both intrinsic and acquired defects in insulin signalling. The cellular insulin resistance in polycystic ovary syndrome has been further shown to involve a novel post-binding defect in insulin signal transduction. Treatment of insulin resistance through lifestyle therapy or with a diabetes drug has become mainstream therapy in women with polycystic ovary syndrome. However, effects with current pharmacologic treatment with metformin tend to be modest, with limited benefit as an agent to treat infertility. Insulin resistance contributes to increased risk for pregnancy complications, diabetes and cardiovascular disease risk profile in polycystic ovary syndrome, which is further exacerbated by obesity. While numerous studies demonstrate increased prevalence of cardiovascular disease risk factors in women with polycystic ovary syndrome, there are limited data showing that women with polycystic ovary syndrome are at increased risk for cardiovascular disease events. Conclusions Insulin resistance is linked to polycystic ovary syndrome. Further study of lifestyle and pharmacologic interventions that reduce insulin resistance, such as metformin, are needed to demonstrate that they are effective in reducing the risk of diabetes, endometrial abnormalities and cardiovascular disease events in women with polycystic ovary syndrome.

AB - Aims To review the relationship between insulin resistance and polycystic ovary syndrome. Methods A literature review. Results Insulin resistance likely plays a central pathogenic role in polycystic ovary syndrome and may explain the pleiotropic presentation and involvement of multiple organ systems. Insulin resistance in the skeletal muscle of women with polycystic ovary syndrome involves both intrinsic and acquired defects in insulin signalling. The cellular insulin resistance in polycystic ovary syndrome has been further shown to involve a novel post-binding defect in insulin signal transduction. Treatment of insulin resistance through lifestyle therapy or with a diabetes drug has become mainstream therapy in women with polycystic ovary syndrome. However, effects with current pharmacologic treatment with metformin tend to be modest, with limited benefit as an agent to treat infertility. Insulin resistance contributes to increased risk for pregnancy complications, diabetes and cardiovascular disease risk profile in polycystic ovary syndrome, which is further exacerbated by obesity. While numerous studies demonstrate increased prevalence of cardiovascular disease risk factors in women with polycystic ovary syndrome, there are limited data showing that women with polycystic ovary syndrome are at increased risk for cardiovascular disease events. Conclusions Insulin resistance is linked to polycystic ovary syndrome. Further study of lifestyle and pharmacologic interventions that reduce insulin resistance, such as metformin, are needed to demonstrate that they are effective in reducing the risk of diabetes, endometrial abnormalities and cardiovascular disease events in women with polycystic ovary syndrome.

UR - http://www.scopus.com/inward/record.url?scp=81355151407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81355151407&partnerID=8YFLogxK

U2 - 10.1111/j.1464-5491.2011.03460.x

DO - 10.1111/j.1464-5491.2011.03460.x

M3 - Review article

C2 - 21950959

AN - SCOPUS:81355151407

VL - 28

SP - 1445

EP - 1454

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 12

ER -